Kashyap Patel, MD, immediate past president of Community Oncology Alliance (COA) and CEO of Carolina Blood and Cancer Care Associates, talks about bringing together different stakeholders in the oncology space in order to benefit patients and providers.
Kashyap Patel, MD, gives a preview of what Community Oncology Alliance (COA) will be focusing on at the 2023 Community Oncology Conference.
Transcript
What are you looking forward to at the 2023 Community Oncology Conference?
This year's COA meeting is going to focus on multiple issues of public interest, beginning from what's happening in the 340B space, what COA is doing in a congressional effort to address the PBMs (pharmacy benefit managers). Because we all understand that the US health care space is quite complicated, with multiple factors beginning from the state, the local, the commercial payer, the Medicare Advantage plans, the MCO (Multi-Criteria Optimization). So all of this makes the space very complicated, and combine that with 340B and health care equity issues.
COA's effort is to try to bring the stakeholders from multiple areas—from the payer space to the provider space to the pharma space—to bring almost like a coalition of like-minded people together that combines the science, the ethics, morality, public policy, and the steps that COA has been taking to ensure that we remain constantly engaged and share information, of COA's bold and widespread effort, beginning from Congress to state level, to ensure that we extend the cause which is advocating for committee oncology policies and patients. We remain united in our efforts to be spokespersons for patients and the providers. In the same token, we also take the leap of ensuring that access to care—which is provided at multiple practices in a smaller rural area, where if we disappear, there will be no access—stays as what it is.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More